This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Dave Garman, PhD
Chief Technology Officer at NoNO, Inc.
Speaker

Profile

Dr. Garman has been with NoNO Inc since 2010 and is currently the Chief Technology Officer, responsible for discovery, preclinical development, manufacturing and intellectual property. Dr. Garman has over 35 years of experience in laboratory science and has spent more than 20 years in biotechnology, holding various positions encompassing discovery and translational research, quality assurance, manufacturing, intellectual property and business development. For the past 13 years, Dr. Garman has been focused on the development of neurotherapeutics for the treatment of stroke and related indications and translation of those compounds to the clinic, including the development of clinical and commercial manufacturing processes and controls. Dr. Garman received his PhD in Developmental Biology from Stanford University.

Agenda Sessions

  • Peptide Validation Strategy to Support Commercial Manufacturing and Distribution

    16:30